Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $29.78

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average recommendation of “Buy” by the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.78.

Several equities research analysts have recently commented on ENGN shares. HC Wainwright began coverage on shares of enGene in a research report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price for the company. Raymond James initiated coverage on shares of enGene in a research report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target for the company. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd.

enGene Stock Down 5.4 %

Shares of NASDAQ:ENGN opened at $6.77 on Friday. The company has a market capitalization of $299.37 million, a price-to-earnings ratio of -11.67 and a beta of -0.65. enGene has a 1 year low of $4.42 and a 1 year high of $18.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The business’s 50-day moving average is $7.36 and its 200-day moving average is $7.50.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. Equities research analysts predict that enGene will post -1.57 earnings per share for the current year.

Institutional Trading of enGene

A number of hedge funds have recently made changes to their positions in the stock. Wolverine Asset Management LLC purchased a new position in shares of enGene in the third quarter worth about $37,000. Point72 Asset Management L.P. grew its stake in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after buying an additional 389,918 shares during the last quarter. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.